Tag Archives: announcement

RESI@JPM Innovation Challenge – Winners Announced

21 Jan

By Nono Hu, Director of Marketing, LSN

Last week, LSN’s Redefining Early Stage Investments (RESI) Conference brought together approximately 350 early stage investors and 300 biotech, medtech and healthcare IT entrepreneurs, our largest crowd to date. The RESI Innovation Challenge received a record number of applicants last fall. The 30 most innovative applicants were hand selected by Life Science Nation’s internal scientific review board and presented their technologies in an exhibition-style format throughout the full-day conference. Here are the top 3 winners!

First Prize Winner: ClearSight

01

ClearSight LLC is commercializing a novel intraocular lens (IOL), the ClearSight IOL, designed to prevent clouding of the lens known as posterior capsular opacification (PCO). PCO is the most frequent surgical complications from cataract surgery, occurring in 25% of patients and costing the U.S. healthcare system $350 million/year. Animal data demonstrates that the ClearSight IOL reduces PCO by 100% in a rabbit model, due to the patent-protected ClearSight IOL design and the addition of a novel microscopic surface texture to prevent cell migration that leads to clouding of the lens. IOLs represent a $1.1 billion U.S. market and $3.7 billion global market.

02

George Ayd, Assistant Vice President, MedMarc; Shravanthi Reddy, COO, ClearSight

 

Second Prize Winner: Eve Medical

03Eve Medical is a Toronto-based medical device company dedicated to improving women’s health. Eve’s core product HerSwab™ makes it easy for women to collect their own samples at home or in clinic to test for common infections that cause cervical cancer, pelvic inflammatory disease and infertility. This saves time, provides privacy and minimizes invasiveness. By reduce barriers to screening, and improving compliance, Eve Medical and HerSwab™ can empower under-served women, improve the reach of existing programs, increase test volumes, and reduce costs for healthcare systems.

04

Michael Quigley, VP of Market Research, LSN; Jessica Ching, CEO, Eve Medical; Dennis Ford, CEO, LSN

 

Third Prize Winner: Briteseed

05The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difficulty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is flexible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workflow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them.

06

Michael Quigley, VP of Market Research, LSN; Mayank Vijay, Head of BD and Operations & Co-founder, Briteseed

 

Tags: , , , ,

RESI Innovation Challenge: Participating Startups Announced

17 Dec

By Dennis Ford, Founder & CEO, LSN

dennis-websit

The RESI Innovation Challenge received a record number of applicants this fall. LSN’s scientific review board assessed and ranked all entrants across a wide range of criteria, from scientific novelty to strength of IP, to select the 30 strongest entrants. We’d now like to announce these successful applicants. These entrepreneurs have been selected by LSN’s scientific validation team to receive a presentation space in the exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. We’re excited to meet all these companies in person in the Exhibitor Hall at RESI, and we hope you’ll join us there to vote for the very best of these cutting-edge life science startups.

IC Logos SF2016

Tags: , , ,

Redefining Early Stage Investments (RESI) Conference: Healthcare IT Investors Panel

17 Dec

By Shaoyu Chang, MD, MPH,  Senior Research Manager, LSN

Shaoyu 10*10

At the intersection between life science and computer science, healthcare IT continues to attract strong interests from both camps. VC funds, big pharmas, and tech corporates are all actively seeking the next big thing in HCIT that would transform healthcare fundamentally.

Some of the biggest players in HCIT investment will speak at RESI San Francisco to share their expertise and advice with entrepreneurs. Moderated by Anne DeGheest, Founder of HealthTech Capital, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these HCIT investors – How do you make your company stand out in this crowded marketplace? What do investors see as the most high-potential fields of innovation in healthcare IT? How do you demonstrate to an investor that your product has the potential to succeed?

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , ,

RESI Panel Announcement: Diagnostic Investors

3 Dec

By Nicholas Civitarese, Research Analyst, LSN

nick-wp

The amount of capital being invested in medical technology and diagnostics is at its highest point since 2008. However, companies in the diagnostics space face some unique challenges in the fundraising landscape.

To inform your fundraising campaign’s direction, Life Science Nation is pleased to announce a panel of six investors with expertise in the diagnostics space for RESI San Francisco on January 12th. Moderated by Akhil Saklecha, Partner at Artiman Ventures, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these diagnostic investors – including best practices for building relationships with diagnostic investors as well as advice on making sure your diagnostic company is positioned as a strong investment opportunity.

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , , ,

RESI SF Panel Annoucement: Big Pharma

25 Nov

By Lucy Parkinson, Director of Research, LSN

One of the key shifts in the life science product development landscape in recent years is that big pharma companies are increasingly looking outward for innovation. Pharma corporate development groups are deploying an array of means to source, evaluate and invest in assets discovered or developed by biotech entrepreneurs.

At RESI San Francisco, the Big Pharma panel will explore the shifting dynamic between big pharma and small biotechs. What can you expect from a pharma company’s evaluation process, and what can you do to position your startup to make a deal?  Panelists will answer these questions and provide their advice on how entrepeneurs can take align themselves with the firms that they represent.

Moderated by Kevin Lynch, Vice President, Scientific Assessment, AbbVie, the panelists are:

If you’d like to hear this panel live at RESI and meet with investors from the pharma world and beyond, you can register for RESI San Francisco now.

RESI-San-Francisco-2016

Tags: , , , , , ,

Panel Announcement: Venture Philanthropy Investors

19 Nov

By Christine A. Wu, Research Analyst, LSN

chrsitine

Venture philanthropy has been a vital source of capital for early stage life science companies over the years. Philanthropic organizations provide more than just financing; a foundation with a niche indication focus may supply a network of experts, patients, and resources in the field. These organizations have an underlying mission to improve specific patient outcomes, going as far as using their financial returns toward further initiatives and investments to achieve their mission. Due to these organizations’ unique missions, LSN has uncovered a number of investment trends and accumulated advice in how to approach venture philanthropy investors.

LSN is pleased to announce a panel of five expert representatives in the venture philanthropy space for the RESI San Francisco Conference on January 12th. Moderated by Chris de Souza, Director of Broadview Ventures, the panel will be joined by:

Panelists will address their specific investment criteria and unique missions; their particular investment decision-making process; the relevant questions to ask and the best approach to reach and heighten their interest; along with important trends to keep in mind.

If venture philanthropy investment is part of your plan to get your company funded, this panel is a fantastic opportunity to extend your network and expand your understanding of these organizations.

RESI-San-Francisco-2016

Tags: , , , , ,

RESI Panel Announcement: Biotech Angels Panel

12 Nov

By Christine A. Wu, Research Analyst, LSN

chrsitine

Angel investors have been one of the first go-to investors as an incredibly important source of capital for fundraising entrepreneurs. They provide early stage companies not only with capital, but also with experience and professional knowledge due to their unique membership composition and investment focus.

Furthermore, there is a continuing trend of angels syndicating to participate in larger investment deals with angel investor rounds growing from $800K in 2014 to over $1M to date in 2015.

LSN has assembled accredited Angel investors particularly interested in biotech therapeutics for RESI San Francisco, occurring on January 12th. The Biotech Angels Panel will be moderated by Karl Handlesman, Founder of Codon Capital, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the trends in angel investment in the bio-pharmaceutical field; the perspective of an angel when approaching a deal in the space; and the best approach to initiate dialogue with an angel investor. Angels will explain their investment preferences and their evaluation criteria, and provide overall advice in how to approach and build relationships with them. This will undoubtedly be a tremendous opportunity for biotech life science entrepreneurs to meet angel investors in person.

RESI-San-Francisco-2016

Tags: , , , , , ,

← Older Entries
Newer Entries →